Nuo Therapeutics, Inc. (AURX) Operating income 2017–2025
Nuo Therapeutics, Inc. (AURX) annual operating income history from SEC filings — each fiscal year as reported.
-$2.5MFY2025 · since FY2017: -$15.5M → -$2.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$2.5M | -2.4% |
| FY2024 | -$2.5M | +22.4% |
| FY2023 | -$3.2M | +4.6% |
| FY2022 | -$3.3M | -3562.3% |
| FY2021 | -$90,670 | +76.0% |
| FY2020 | -$378,059 | +61.0% |
| FY2019 | -$969,198 | +35.6% |
| FY2018 | -$1.5M | +90.3% |
| FY2017 | -$15.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AURX financial trends
AURX RevenueAURX Net incomeAURX Net marginAURX Gross profitAURX Gross marginAURX Operating marginAURX Operating cash flowAURX Free cash flowAURX Capital expendituresAURX Return on equityAURX Stock buybacksAURX Dividends paidAURX Total assetsAURX Total liabilitiesAURX Shareholders’ equityAURX overview →